Pneumothorax Infection Treatment Market Size, Share, and Growth Forecast, 2026 - 2033

The global pneumothorax infection treatment market size is likely to be valued at US$34.1 billion in 2026 and is expected to reach US$49.0 billion by 2033, growing at a CAGR of 5.3% during the forecast period from 2026 to 2033, driven by the rising burden of respiratory disorders, increasing hospital admissions for pneumothorax, and advances in minimally invasive pleural procedures.

The WHO reported in 2026 that COPD caused 3.4 million deaths globally in 2023, reinforcing the burden of underlying respiratory conditions associated with secondary pneumothorax. In 2025, the WHO also reported 81.7 million people living with chronic respiratory diseases in Europe, supporting continued demand for diagnosis, chest drainage, and pneumothorax management solutions.

Driver - Rising Prevalence of Chronic Respiratory Diseases

The rising prevalence of chronic respiratory diseases is a major driver for the pneumothorax infection treatment market. Conditions such as chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, and emphysema can weaken lung tissue and increase the likelihood of secondary pneumothorax. The World Health Organization reported that COPD caused 3.5 million deaths globally in 2021, highlighting the respiratory disease burden.

As populations age and exposure to tobacco smoke and air pollution remains significant, the number of patients vulnerable to pneumothorax complications is expected to increase. This expanding patient pool supports demand for chest drainage devices, diagnostic imaging, hospitalization, and treatment approaches. Healthcare systems are increasingly encountering pneumothorax in patients with complex conditions, creating sustained demand for diagnosis and intervention.

Secondary spontaneous pneumothorax can require urgent management because underlying lung disease may reduce reserve and complicate recovery. Growing awareness among clinicians, improved emergency care pathways, and broader access to diagnostics are strengthening treatment capabilities. Aging populations are contributing to a larger pool of patients with chronic pulmonary disorders, particularly in developed markets. These trends encourage hospitals to invest in chest drainage systems, imaging equipment, and follow-up technologies.

Restraint - Diagnostic Complexity and Variability in Presentation

Diagnostic complexity and variability in presentation act as important restraints, as pneumothorax symptoms can overlap with other respiratory and cardiovascular conditions. Patients may present with chest pain, shortness of breath, reduced oxygenation, or subtle clinical findings when pneumothorax is small or occurs alongside underlying lung disease. Physical examination alone may therefore be insufficient, requiring confirmation through chest X-ray, ultrasound, or computed tomography. Differences in clinical protocols, equipment availability, and physician experience can create variability in diagnosis and treatment decisions across healthcare settings.

The challenge becomes more pronounced in emergency departments, rural facilities, and lower-resource healthcare systems where imaging or experienced personnel may not always be immediately available. Ultrasound can improve bedside assessment, while CT provides visualization for complex cases, but differences in training and institutional protocols influence utilization. Iatrogenic pneumothorax can also be detected during or after invasive procedures, requiring monitoring and rapid confirmation.

Opportunity - Technological Convergence and Minimally Invasive Solutions

Technological convergence presents a significant opportunity as imaging, artificial intelligence, portable monitoring, and minimally invasive treatment technologies complement one another in pneumothorax management. Point-of-care ultrasound can support rapid bedside detection, while digital chest drainage systems can continuously monitor air leaks and provide objective data for decisions. Artificial intelligence can assist image interpretation and workflow prioritization, particularly in high-volume emergency environments.

Integration of these technologies with electronic health records and remote monitoring platforms could enable coordinated care. Such convergence may improve diagnostic speed, treatment precision, and patient monitoring while supporting shorter hospital stays and expanding opportunities for outpatient management where clinically appropriate. Minimally invasive solutions create opportunities for manufacturers to develop smaller, portable, and user-friendly systems that support earlier mobilization and reduce hospital resource requirements.

Digital drainage platforms can provide quantitative air-leak measurements, helping clinicians assess progress and make informed decisions about tube removal. Advances in catheter design, imaging guidance, and remote monitoring may improve procedural safety and follow-up. Partnerships between medical device companies, hospitals, and technology providers can accelerate commercialization of integrated solutions.

Product Type Insights

Secondary spontaneous pneumothorax is expected to lead, accounting for 30% of revenue in 2026, as it frequently occurs in patients with pre-existing pulmonary conditions, particularly COPD, emphysema, and other chronic lung disorders. The increasing prevalence of chronic respiratory diseases contributes to a persistent clinical burden and supports demand for effective pneumothorax diagnosis and treatment. Management often requires rapid assessment, chest drainage, and monitoring to prevent complications. For example, the British Thoracic Society provides clinical guidance for managing spontaneous pneumothorax, including cases associated with underlying lung disease.

Injury-related pneumothorax is likely to represent the fastest-growing segment, supported by the continued occurrence of chest trauma from road accidents, falls, sports injuries, and other emergencies. Traumatic pneumothorax requires rapid recognition because air accumulation in the pleural cavity can compromise respiratory function and may progress to life-threatening conditions. Growing emphasis on emergency trauma care, portable imaging, and rapid chest-drainage procedures is supporting market adoption. A notable example includes ATLS guidelines from the American College of Surgeons emphasize prompt assessment and management of traumatic chest injuries, including pneumothorax.

Diagnosis Type Insights

Chest X-ray is projected to lead the market, capturing around 55% of the revenue share in 2026, supported by its broad availability, established clinical workflow, relatively rapid examination, and widespread use in emergency and hospital settings. It provides physicians with a practical method for identifying pleural air and assessing the extent of lung collapse. Chest radiography is particularly valuable where advanced imaging equipment may not be immediately accessible. Continued utilization across emergency departments, respiratory units, and trauma facilities supports its leading position in pneumothorax diagnosis. A notable example is that the American College of Radiology recognizes chest radiography as an important imaging modality for evaluating suspected pneumothorax.

Ultrasound is likely to be the fastest-growing diagnostic modality due to increasing adoption of portable point-of-care imaging in emergency departments, intensive-care units, ambulances, and bedside clinical environments. Unlike conventional radiography, ultrasound does not use ionizing radiation and can be performed rapidly without transporting critically ill patients. Its growing role in focused bedside assessment makes it particularly useful for trauma and emergency care, where timely diagnosis can influence treatment decisions. The World Health Organization supports the use of point-of-care ultrasound in appropriate clinical and emergency-care settings.

North America Pneumothorax Infection Treatment Market Trends

North America is anticipated to be the leading region, accounting for a market share of 36% in 2026, supported by advanced emergency-care infrastructure, established thoracic-surgery capabilities, and growing use of minimally invasive and digital chest-drainage technologies. The region is also benefiting from greater adoption of portable monitoring systems and evidence-based pneumothorax management. Increasing awareness of rapid diagnosis and management of traumatic and spontaneous pneumothorax supports demand for treatment solutions.

U.S. Pneumothorax Infection Treatment Market Trends

The U.S. is expected to dominate the regional market, accounting for approximately 80% of the North America market in 2026, driven by sophisticated emergency departments, trauma centers, and thoracic-surgery facilities. Advanced imaging supports rapid identification of pneumothorax. Hospitals are increasingly emphasizing evidence-based and minimally invasive management. Digital chest-drainage systems are gaining attention for objective air-leak monitoring. Trauma-care protocols continue to support demand for rapid chest drainage when clinically indicated.

Canada Pneumothorax Infection Treatment Market Trends

Canada is likely to be a significant market for pneumothorax infection treatment, holding approximately 20% of the North America market in 2026, supported by established hospital-based respiratory and thoracic-care services. Emergency departments remain important treatment settings for acute pneumothorax cases. Clinical adoption is increasingly influenced by international evidence-based pneumothorax guidelines. Portable diagnostic technologies can support bedside assessment in emergency and critical-care environments. Chest drainage remains important for patients requiring intervention.

Europe Pneumothorax Infection Treatment Market Trends

Market growth is driven by standardized clinical guidelines, minimally invasive interventions, ambulatory treatment, and digital chest-drainage technologies. The 2024 ERS/EACTS/ESTS guideline recommends conservative management for selected stable patients and supports needle aspiration and ambulatory management in appropriate cases.

U.K. Pneumothorax Infection Treatment Market Trends

The U.K. is likely to be a significant market for pneumothorax infection treatment, accounting for 15% of Europe market share in 2026. The U.K. has established pathways for emergency and respiratory management of pneumothorax. NICE guidance has specifically supported consideration of Thopaz+ for pneumothorax requiring chest drainage. The NHS provides treatment through emergency, respiratory, and thoracic-surgery services. Ambulatory management is receiving greater attention for appropriately selected patients. Needle aspiration and conservative approaches are increasingly incorporated into evidence-based treatment strategies.

Germany Pneumothorax Infection Treatment Market Trends

Germany is anticipated to dominate the regional market, accounting for around 37% of the Europe market share in 2026. Germany has a well-developed hospital network supporting respiratory and thoracic care. Pneumothorax is formally classified within Germany’s ICD coding system. Both spontaneous and traumatic pneumothorax are recognized clinical categories. Thoracic surgery centers provide advanced treatment for recurrent and complicated cases. European evidence-based guidelines are influencing treatment decisions. Minimally invasive and ambulatory approaches are becoming increasingly relevant for suitable patients.

Asia Pacific Pneumothorax Infection Treatment Market Trends

The Asia Pacific region is likely to be the fastest-growing region in pneumothorax infection treatment market in 2026. Its expanding hospital infrastructure, increasing emergency-care capacity, rising availability of diagnostic imaging, and growing adoption of modern thoracic-treatment technologies. The region is also seeing greater clinical interest in conservative and minimally invasive management for appropriately selected spontaneous pneumothorax patients. Recent research from India highlights continued evaluation of conservative approaches, while digital drainage systems are being studied for traumatic pneumothorax management.

China Pneumothorax Infection Treatment Market Trends

China is projected to dominate the regional market, holding around a 30% share of the market in 2026. China has a large and expanding hospital system supporting respiratory and thoracic disease management. Improving access to advanced imaging is strengthening pneumothorax diagnosis. Large tertiary hospitals are important centers for thoracic surgery and complex respiratory care. The country is increasingly emphasizing standardized clinical diagnosis and treatment. The Chinese Medical Association continues to develop updated evidence-based clinical guidelines across respiratory and thoracic medicine.

India Pneumothorax Infection Treatment Market Trends

India is expected to emerge as a significant market, accounting for approximately 22% share in 2026. India is experiencing increasing demand for efficient pneumothorax diagnosis and treatment across tertiary and emergency-care hospitals. Government standard-treatment guidance supports appropriate chest-drainage management for indicated pneumothorax cases. Major trauma centers continue to require rapid intervention for traumatic pneumothorax. Growing availability of CT and X-ray imaging is strengthening diagnostic capabilities.

The global pneumothorax infection treatment market exhibits a moderately fragmented structure, driven by increasing demand for chest drainage systems, minimally invasive interventions, portable treatment technologies, and improved air-leak monitoring. Competition is shaped by established medical-device manufacturers and specialized thoracic-care companies offering drainage systems, catheters, thoracic kits, and digital monitoring solutions.

Key leaders include Teleflex, Medela, Getinge, Becton, Dickinson and Company, Medtronic, B. Braun, Cook Medical, and Rocket Medical. Recent industry activity indicates increasing emphasis on digital chest drainage and objective air-leak measurement. These players compete through product innovation, digitalization, clinical evidence, portfolio expansion, and stronger hospital distribution networks.

Key Industry Developments:

• In May 2026, BD Centrovena One Insertion System: Becton, Dickinson and Company (BD) announced the market launch of the Centrovena One Insertion System, a device designed to support vascular access procedures.